|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Budd-Chiari syndrome:Etiology,pathogenesis and diagnosis显示文摘Budd-Chiari syndrome is a congestive hepatopathy caused by blockage of hepatic veins. This syndrome occurs in 1/100 000 in the general population. Hypercoagulable state could be identified in 75% of the patients; more than one etiologic factor may play a role in 25% of the patients. Primary myeloproliferative diseases are the leading cause of the disease. Two of the hepatic veins must be blocked for clinically evident disease. Liver congestion and hypoxic damage of hepatocytes eventually result in predominantly centrilobular fibrosis. Doppler ultrasonography of the liver should be the initial diagnostic procedure. Hepatic venography is the reference procedure if required. Additionally liver biopsy may be helpful for differential diagnosis. The prognosis of the chronic form is acceptable compared to other chronic liver diseases. | Musa Aydinli Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，19： | 52 |
| 2 | How useful is rectal endosonography in the staging of rectal cancer?显示文摘It is essential in treating rectal cancer to have adequate preoperative imaging,as accurate staging can influence the management strategy,type of resection,and candidacy for neoadjuvant therapy.In the last twenty years,endorectal ultrasound(ERUS) has become the primary method for locoregional staging of rectal cancer.ERUS is the most accurate modality for assessing local depth of invasion of rectal carcinoma into the rectal wall layers(T stage) .Lower accuracy for T2 tumors is commonly reported,which could lead to sonographic overstaging of T3 tumors following preoperative therapy.Unfortunately,ERUS is not as good for predicting nodal metastases as it is for tumor depth,which could be related to the unclear definition of nodal metastases.The use of multiple criteria might improve accuracy.Failure to evaluate nodal status could lead to inadequate surgical resection.ERUS can accurately distinguish early cancers from advanced ones,with a high detection rate of residual carcinoma in the rectal wall.ERUS is also useful for detection of local recurrence at the anastomosis site,which might require fine-needle aspiration of the tissue.Overstaging is more frequent than understaging,mostly due to inflammatory changes.Limitations of ERUS are operator and experiencedependency,limited tolerance of patients,and limited range of depth of the transducer.The ERUS technique requires a learning curve for orientation and identification of images and planes.With sufficient time and effort,quality and accuracy of the ERUS procedure could be improved. | Taylan Kav Yusuf Bayraktar | 2010 | World Journal of Gastroenterology2010，16，6： | 34 |
| 3 | Hepatic venous outflow obstruction:Three similar syndromes显示文摘Our goal is to provide a detailed review of veno- occlusive disease (VOD), Budd-Chiari syndrome (BCS), and congestive hepatopathy (CH), all of which results in hepatic venous outflow obstruction. This is the first article in which all three syndromes have been reviewed, enabling the reader to compare the characteristics of these disorders. The histological findings in VOD, BCS, and CH are almost identical: sinusoidal congestion and cell necrosis mostly in perivenular areas of hepatic acini which eventually leads to bridging fibrosis between adjacent central veins. Tender hepatomegaly with jaundice and ascites is common to all three conditions. However, the clinical presentation depends mostly on the extent and rapidity of the outflow obstruction. Although the etiology and treatment are completely different in VOD, BCS, and CH; the similarities in clinical manifestations and liver histology may suggest a common mechanism of hepatic injury and adaptation in response to increased sinusoidal pressure. | Ulas Darda Bayraktar Soley Seren Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，13： | 28 |
| 4 | Molecular basis and management of gastrointestinal stromal tumors显示文摘Molecularly targeted agents have dramatically impacted the management of several cancers. Targeting KIT has led to a new treatment paradigm in gastrointestinal stromal tumors (GISTs). KIT is a cell surface receptor with tyrosine kinases that, upon binding of its ligand, stem cell factor, activates various signaling pathways. Imatinib and sunitinib, both tyrosine kinase inhibitors directed to KIT, were approved for firstand secondline treatment of metastatic and unresectable GISTs. In this article, we will review the molecular pathogenesis of GISTs followed by a discussion of imatinib and sunitinib’s role in the treatment of GISTs. Finally, we will introduce novel therapeutic options for imatiniband sunitinib-resistant GISTs. | Ulas D Bayraktar Soley Bayraktar Caio M Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，22： | 23 |
| 5 | Experience of a single center with congenital hepatic fibrosis:A review of the literature显示文摘Congenital hepatic fibrosis(CHF) is an autosomal recessive inherited malformation defined pathologically by a variable degree of periportal fibrosis and irregularly shaped proliferating bile ducts.It is one of the fibropolycystic diseases,which also include Caroli disease,autosomal dominant polycystic kidney disease,and autosomal recessive polycystic kidney disease. Clinically it is characterized by hepatic fibrosis,portal hypertension,and renal cystic disease.CHF is known to occur in association with a range of both inherited and non-inherited disorders,with multiorgan involvement,as a result of ductal plate malformation.Because of the similarities in the clinical picture,it is necessary to differentiate CHF from idiopathic portal hypertension and early liver cirrhosis,for which a liver biopsy is essential. Radiological tests are important for recognizing involvement of other organ systems.With regards to our experience at Hacettepe University,a total of 26 patients have been diagnosed and followed-up between 1974 and 2009 with a diagnosis of CHF.Presentation with Caroli syndrome was the most common diagnosis,with all such patients presenting with symptoms of recurrentcholangitis and symptoms related to portal hypertension. Although portal fibrosis is known to contribute to the ensuing portal hypertension,it is our belief that portal vein cavernous transformation also plays an important role in its pathogenesis.In all patients with CHF portal vein morphology should be evaluated by all means since portal vein involvement results in more severe and complicated portal hypertension.Other associations include the Joubert and Bardet-Biedl syndromes. | Ali Shorbagi Yusuf Bayraktar | 2010 | World Journal of Gastroenterology2010，16，6： | 22 |
| 6 | Clinical characteristics of Caroli's syndrome显示文摘Caroli's syndrome is characterized by multiple segmental cystic or saccular dilatations of intrahepatic bile ducts associated with congenital hepatic fibrosis. The clinical features of this syndrome reflect both the characteristics of congenital hepatic fibrosis such as portal hypertension and that of Caroli's disease named as recurrent cholangitis and cholelithiasis. The diagnosis depends on both histology and imaging methods which can show the communication between the sacculi and the bile ducts. Treatment consists of symptomatic treatment of cholangitis attacks by antibiotics, some endoscopic, radiological and surgical drainage procedures and surgery. Liver transplantation seems the ultimate treatment for this disease. Prognosis is fairly good unless recurrent cholangitis and renal failure develops. | Ozlem Yonem Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，13： | 22 |
| 7 | Portal hypertension due to portal venous thrombosis:Etiology, clinical outcomes显示文摘The thrombophilia in adult life has major implications in the hepatic vessels. The resulting portal vein thrombosis has various outcomes and complications. Esophageal varices, portal gastropathy, ascites, severe hypersplenism and liver failure needing liver transplantation are known well. The newly formed collateral venous circulation showing itself as pseudocholangicarcinoma sign and its possible clinical reflection as cholestasis are also known from a long time. The management strategies for these complications of portal vein thrombosis are not different from their counterpart which is cirrhotic portal hypertension, but the prognosis is unquestionably better in former cases. In this review we present and discuss the portal vein thrombosis, etiology and the resulting clinical pictures. There are controversial issues in nomenclature, management (including anticoagulation problems), follow up strategies and liver transplantation. In the light of the current knowledge, we discuss some controversial issues in literature and present our experience and our proposals about this group of patients. | Ozgur Harmanci Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，18： | 21 |
| 8 | How can portal vein cavernous transformation cause chronic incomplete biliary obstruction?显示文摘Biliary disease in the setting of non-cirrhotic portal vein thrombosis(and similarly in portal vein cavernous transformation) can become a serious problem during the evolution of disease.This is mostly due to portal biliary ductopathy.There are several mechanisms that play a role in the development of portal biliary ductopathy,such as induction of fibrosis in the biliary tract(due to direct action of dilated peribiliary collaterals and/or recurrent cholangitis),loss of biliary motility,chronic cholestasis(due to fibrosis or choledocholithiasis) and increased formation of cholelithiasis(due to various factors).The management of cholelithiasis in cases with portal vein cavernous transformation merits special attention.Because of a heterogeneous clinical presentation and concomitant pathophysiological changes that take place in biliary anatomy,diagnosis and therapy can become very complicated.Due to increased incidence and complications of cholelithiasis,standard treatment modalities like sphincterotomy or balloon sweeping of bile ducts can cause serious problems.Cholangitis,biliary strictures and hemobilia are the most common complications that occur during management of these patients.In this review,we specifically discuss important issues about bile stones related to bile duct obstruction in non-cirrhotic portal vein thrombosis and present evidence in the current literature. | Ozgur Harmanci Yusuf Bayraktar | 2012 | World Journal of Gastroenterology2012，18，26： | 19 |
| 9 | Outcomes of partial splenic embolization in patients with massive splenomegaly due to idiopathic portal hypertension显示文摘AIM To determine the outcomes of partial splenic em-bolization(PSE) for massive splenomegaly due to idiopathic portal hypertension(IPH).METHODS In this prospective study, we evaluated the charac-teristics and prognosis of consecutive patients with IPH who underwent PSE for all indications at a single medical center between June 2009 and January 2015. The inclusion criteria were: presence of hypersplenism, massive splenomegaly, and resultant pancytopenia. The exclusion criteria were: presence of other diseases causing portal hypertension. During the post-PSE period, the patients were hospitalized. All patients underwent abdominal computed tomography imaging 4 wk post-PSE to determine total splenic and non-infarcted splenic volumes.RESULTS A total of 11 patients, with median age of 33.27 ± 4.8 years, were included in the study. Mean spleen size was 22.9 cm(21-28 cm), and severe hypersplenismwas diagnosed in all patients before PSE. Post-PSE, leukocyte and platelet counts increased significantly, reaching peak levels in the second week with gradual decreases thereafter. Liver function tests did not exhibit significant changes during post-intervention follow-up. All patients developed post-embolization syndrome, and one patient experienced serious complications; all complications were successfully treated with conservative therapy and no death occurred. CONCLUSION Our findings showed that PSE has a lower complication rate than previously-reported surgical complication rates, which supports this intervention as a viable alternative for high-risk operable patients with severe hypersplenism. | Omer Ozturk Gonca Eldem Bora Peynircioglu Taylan Kav Aysegul Gormez Barbaros Erhan Cil Ferhun Balkanci Cenk Sokmensuer Yusuf Bayraktar | 2016 | World Journal of Gastroenterology2016，22，43： | 18 |
| 10 | Clinical characteristics of Caroli’s disease显示文摘Caroli's disease is a rare congenital condition chara- cterized by non-obstructive saccular or fusiform dilatation of larger intrahepatic bile ducts. Cholangitis, liver cirrhosis, and cholangiocarcinoma are its potential complications. The diagnosis of Caroli's disease depends on demonstrating that the cystic lesions are in continuity with the biliary tree which can be showed by ultrasonography, computerized tomography, endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography or magnetic resonance cholangiopancreatography. Treatment of Caroli's disease relies on the location of the biliary abnormalities. While localized forms confined to one lobe can be treated with surgery, liver transplantation is the only effective modality for diffuse forms. Although a rare disorder; Caroli's disease should always be considered in the differential diagnosis of chronic cholestasis of unknown cause. | Ozlem Yonem Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，13： | 18 |
| 11 | Etiology and consequences of thrombosis in abdominal vessels显示文摘能在成年生命先天或获得的血栓形成倾向在腹的容器有主要含意。产生的门静脉血栓, Budd-Chiari 症候群和 mes 伤寒静脉血栓有许多后果从急腹症到唯一的发现在是各类血细胞减少的长期的肝肿大和甚至完全无征状的病人。复杂并发症喜欢食道的静脉曲张,门胃病,腹水,严重脾机能亢进,肝失败要求肝移植是众所周知的。作为胆汁郁积显示出 pseudocholangiocarcinoma 签名的本身和它的可能的临床的思考的并行的静脉的循环的有趣的特征也从很长时间被知道。为 intraabdominal 容器血栓的这些复杂并发症的管理策略不与他们是肝脏硬化症的门静脉高血压的对应物不同,但是预后在以前的情况中无疑地更好。在这评论,我们介绍了并且讨论腹的静脉血栓形成,病原学并且结果临床的图画。包括反凝结问题在名称,和管理有争论问题并且在策略上面列在后面。考虑到当前的知识,我们在文学讨论了一些争论问题并且关于这组病人介绍了我们的经验和我们的建议。 | Yusuf Bayraktar Ozgur Harmanci | 2006 | World Journal of Gastroenterology2006，12，8： | 17 |
| 12 | Cholangiocarcinoma:A compact review of the literature显示文摘Cholangiocarcinoma(CC) is a devastating cancer aris-ing from biliary epithelia.Unfortunately,the incidence of this disease is increasing in Western countries.These tumors progress insidiously,and liver failure,biliary sepsis,malnutrition and cancer cachexia are general modes of death associated with this disease.To date,no established therapy for advanced dis-ease has been established or validated.However,our knowledge in tumor biology is increasing dramatically and new drugs are under investigation for treatment of this notorious tumor.In clinical practice,there are better diagnostic tools in use to facilitate an earlier diagnosis of CC,at least in those patients with known risk factors.CC is resectable for cure in only a small percentage of patients.Preoperative staging for vas-cular and biliary extension of CC is very important in this tumor.Laparoscopy and recently endosonography seem to protect against unnecessary laparotomies in these patients.During the last 15 years,aggressive surgical approaches,including combined liver resec-tions and vascular reconstructive surgical expertise,have improved survival in patients with CC.Surgery is contraindicated in CC cases having primary sclerosing cholangitis(PSC).Although CC was previously consid-ered a contraindication to liver transplantation,new cautious protocols,including neo-adjuvant chemora-diation therapies and staging procedures before the transplantation,have made it possible to achieve long-term survival after liver transplantation in this disease.New ablative therapies with photodynamic therapy,intraductal high-intensity ultrasonography and chemo-therapy-impregnated plastic biliary endoprosthesis are important steps in the palliative management of extra-hepatic CCs.Radiofrequency and chemo-embolization methods are also applicable for intra-hepatic CCs as palliative modes of treatment.We need more prospec-tive randomized controlled trials to evaluate the role of the new emerging therapies for CC patients. | Yucel Ustundag Yusuf Bayraktar | 2008 | World Journal of Gastroenterology2008，14，42： | 16 |
| 13 | How much helpful is the capsule endoscopy for the diagnosis of small bowel lesions?显示文摘瞄准:估计实际上实用性和在有怀疑的小肠损害的一组病人的这个新方法的诊断产量。方法:囊内视镜(CE ) 由使用 M2A 囊内诊镜 TM 的检查(给定的成像, Yoqneam,以色列) 在三十九个病人被执行(26 男性, 13 女性) 与怀疑的小肠的损害。创作病人如下:在 23 个病人的阴暗胃肠的流血,已知的 Crohn 在 6 个病人, CE 在被用来评估疾病的严厉和延期的疾病,在 8 个病人,的长期的腹泻在一个病人的腹的疼痛和在有未知起源的一个病人的恶意。结果:在二个病人, CE 失败了。不同畸形总的来说在 26 个病人被揭示。畸形的察觉率在有阴暗胃肠的流血的病人之中是最高的,流血的来源与阴暗流血在 23 个病人中的 17 个被表明(73.9%) 。Entero-Behcet 被 CE 作为阴暗胃肠的流血的来源在二个病人诊断。在有已知的 Crohn 的疾病的 6 个病人, CE 揭示了疾病延期的更好的评估。在 8 中的 3 个(37.5%) 有长期的腹泻的病人;CE 作为长期的腹泻的原因揭示了一些粘膜畸形。在有 unexplained 的一个病人腹的疼痛并且在有未知起源的一个癌症病人,, CE 检查是正常的。结论:在我们的相对小的系列,我们发现囊内视镜检查法在阴暗胃肠的流血、长期的腹泻的诊断并且在估计 Crohn 的疾病的延期特别地是一个有用诊断工具。 | Osman Ersoy Bulent Sivri Serap Arslan Figen Batman Yusuf Bayraktar | 2006 | World Journal of Gastroenterology2006，12，24： | 15 |
| 14 | Five years' experience with capsule endoscopy in a single center显示文摘Capsule endoscopy (CE) is a novel technology that facilitates highly effective and noninvasive imaging of the small bowel. Although its effi cacy in the evaluation of obscure gastrointestinal bleeding (OGIB) has been proven in several trials, data on uses of CE in different small bowel diseases are rapidly accumulating in the literature, and it has been found to be superior to alternative diagnostic tools in a range of such diseases. Based on literature evidence, CE is recommended as a first-line investigation for OGIB after negative bi-directional endoscopy. CE has gained an important role in the diagnosis and follow-up of Crohn's disease and celiac disease and in the surveillance of small bowel tumors and polyps in selected patients. Capsule retention is the major complication, with a frequency of 1%-2%. The purpose of this review was to discuss the procedure, indications, contraindications and adverse effects associated with CE. We also review and share our five-year experience with CE in various small bowel diseases. The recently developed balloon-assisted enteroscopies have both diagnostic and therapeutic capability. At the present time, CE and balloon-assisted enteroscopies are complementary techniques in the diagnosis and management of small bowel diseases. | Taylan Kav Yusuf Bayraktar | 2009 | World Journal of Gastroenterology2009，15，16： | 14 |
| 15 | Treatment of iron deficiency anemia associated with gastrointestinal tract diseases显示文摘The gastrointestinal (GI) tract is a common site of bleeding that may lead to iron deficiency anemia (IDA). Treatment of IDA depends on severity and acuity of patients’ signs and symptoms. While red blood cell transfusions may be required in hemodynamically unstable patients, transfusions should be avoided in chronically anemic patients due to their potential side effects and cost. Iron studies need to be performed after episodes of GI bleeding and stores need to be replenished before anemia develops. Oral iron preparations are efficacious but poorly tolerated due to non-absorbed iron-mediated GI side effects. However, oral iron dose may be reduced with no effect on its efficacy while decreasing side effects and patient discontinuation rates. Parenteral iron therapy replenishes iron stores quicker and is better tolerated than oral therapy. Serious hypersensitive reactions are very rare with new intravenous preparations. While data on worsening of inflammatory bowel disease (IBD) activity by oral iron therapy are not conclusive, parenteral iron therapy still seems to be advantageous in the treatment of IDA in patients with IBD, because oral iron may not be sufficient to overcome the chronic blood loss and GI side effects of oral iron which may mimic IBD exacerbation. Finally, we believe the choice of oral vs parenteral iron therapy in patients with IBD should primarily depend on acuity and severity of patients’ signs and symptoms. | Ulas D Bayraktar Soley Bayraktar | 2010 | World Journal of Gastroenterology2010，16，22： | 13 |
| 16 | Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer显示文摘In spite of advances made in the management of the other more common cancers of the gastrointestinal tract,significant progress in the treatment of pancreatic cancer remains elusive.Nearly as many deaths occur from pancreatic cancer as are diagnosed each year reflecting the poor prognosis typically associated with this disease.Until recently,the only treatment with an impact on survival was surgery.In the palliative setting,gemcitabine(Gem) has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil.Since then,clinical trials have explored the pharmacokinetic modulation of Gem by fixed dose administration and the combination of Gem with other cytotoxic or the biologically'targeted'agents.However,promising trial results in small phaseⅡtrials have not translated into survival improvements in larger phaseⅢrandomized trials in the advanced disease setting.Two trials have recently reported modest survival improvements with the use of combination treatment with Gem and capecitabine(United Kingdom National Cancer Research GEMCAP trial) or erlotinib(National Cancer Institute of CanadaClinical Trials Group PA.3 trial) .This review will focus on the use of systemic therapy for advanced and metastatic pancreatic cancer,summarizing the results of several recent clinical trials and discuss their implications for clinical practice.We will also discuss briefly the second-line chemotherapy options for advanced pancreatic cancer. | Soley Bayraktar Ulas Darda Bayraktar Caio Max Rocha-Lima | 2010 | World Journal of Gastroenterology2010，16，6： | 11 |
| 17 | Is portal vein cavernous transformation a component of congenital hepatic fibrosis?显示文摘Congenital hepatic fibrosis (CHF) is an autosomal recessive disorder that belongs to the family of fibropolycystic liver diseases. This family includes a spectrum of disorders which are usually found in combination with each other and are usually inherited. Clinically fibropolycystic diseases have three effects being present in different proportions, those of a space occupying lesion, of portal hypertension and of cholangitis. In most patients, the first manifestations of CHF are signs and symptoms related to portal hypertension such as splenomegaly and varices. Portal hypertension in these patients has been attributed to the hypoplasia or compression of the portal vein radicles in the fibrous bands. Cavernous transformation of the portal vein (CTPV) is a relatively rare condition resulting from extrahepatic portal vein obstruction with recanalization or collateral vein formation to bypass the obstruction. It has been found that patients with CHF having an accompanying CTPV have relatively large splenomegaly and suffers more frequent episodes of bleeding from esophageal varices.We believe that CTPV is a congenital component of CHF and also one of the important causative factors of portal hypertension in these patients. | Ozlem Yonem Yusuf Bayraktar | 2007 | World Journal of Gastroenterology2007，13，13： | 9 |
| 18 | Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma显示文摘Non-small-cell lung cancer(NSCLC)remains the leading cause of cancer-related death in both men and women in the United States.Platinum-based doublet chemotherapy has been a standard for patients with advanced stage disease.Improvements in overall survival and quality of life have been modest.Improved knowledge of the aberrant molecular signaling pathways found in NSCLC has led to the development of biomarkers with associated targeted therapeutics,thus changing the treatment paradigm for many NSCLC patients.In this review,we present a summary of many of the currently investigated biologic targets in NSCLC,discuss their current clinical trial status,and also discuss the potential for development of other targeted agents. | Soley Bayraktar Caio M Rocha-Lima | 2013 | World Journal of Clinical Oncology2013，4，2： | 8 |
| 19 | Does physical therapy and rehabilitation improve outcomes for diabetic foot ulcers?显示文摘One of the most common and serious complications of diabetes mellitus is ulceration of the foot. Among persons with diabetes, 12%-25% will present to a healthcare institution for a foot disorder during their lifespan. Despite currently available medical and surgical treatments, these are still the most common diabetes-related cause of hospitalization and of lower extremity amputations. Thus, many adjunctive and complementary treatments have been developed in an attempt to improve outcomes. We herein review the available literature on the effectiveness of several treatments, including superficial and deep heaters, electro-therapy procedures, prophylactic methods, exercise and shoe modifications, on diabetic foot wounds. Overall, although physical therapy modalities seem to be useful in the treatment of diabetic foot wounds, further randomized clinical studies are required. | Yasemin Turan Bulent M Ertugrul Benjamin A Lipsky Kevser Bayraktar | 2015 | World Journal of Experimental Medicine2015，5，2： | 7 |
| 20 | Primary sclerosing cholangitis-What is the difference between east and west?显示文摘Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease characterized by inflammation and fibrotic obliteration of the hepatic biliary tree. It is commonly associated with inflammatory bowel disease (IBD). A number of complications can occur which require special consideration, the most important of which is the development of cholangiocellular carcinoma (CCC). Unfortunately, no medical therapy is currently available for the underlying liver disease. Liver transplantation is an effective, life-extending option for patients with advanced PSC. Geographical variations between East and West include a second peak for age with a lower association with IBD in a Japanese population and female predominance in a lone study from Turkey. The clinical and biochemical Mayo criteria may not be universally applicable, as different patients show variations regarding the initial presentation and natural course of the disease. Directing research towards explaining these geographical differences and understanding the pathogenesis of PSC is required in order to develop better therapies for this devastating disease. | Ali Shorbagi Yusuf Bayraktar | 2008 | World Journal of Gastroenterology2008，14，25： | 6 |
您所在的机构暂未开通此部分的功能，请联系管理员